Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02301130
Title Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Kyowa Hakko Kirin Pharma, Inc.
Indications

Advanced Solid Tumor

Therapies

Mogamulizumab

Durvalumab

Tremelimumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.